Pharma major Ranbaxy Laboratories today said it has launched a new dermatological product Lulifin in the Indian market. This follows a strategic in-licensing agreement with Summit Pharmaceuticals International Corporation, Japan, Ranbaxy said.
"It is well recognised that in the post patent era, licensing would be the key strategy to bring new chemical entities to India. Dermatology is one of the top priority therapeutic areas for us and we are pleased to introduce Lulifin in the Indian market," said Sanjeev Dani, senior vice president and regional director, Asia, CIS and Africa, Ranbaxy.
Lulifin is a topical imidazole used for the treatment of cutaneous mycoses with disadvantages like long duration of therapy, which leads to poor compliance and high relapse rate.